慢性脱髓鞘多发性神经炎市场：按分销管道、给药途径和地区分析与预测（2025 年至 2035 年）

慢性脱髓鞘多发性神经炎市场的主要成长要素之一是对创新有效治疗方法的需求不断增加。

随着医护人员和患者对慢性脱髓鞘多发性神经炎认识的不断提高，该疾病的诊断率显着上升，对更先进治疗方法的需求也随之增加。由于静脉注射免疫球蛋白 (IVIG) 和血浆置换等传统治疗方法并非对所有患者都有效，因此针对生物製药和口服免疫抑制剂等新治疗方案有助于提供更个人化和有效的护理。

此外，慢性脱髓鞘多发性神经炎）认知度的提高、诊断技术的进步以及全球自体免疫疾病的增多，也促进了患者群体的扩大。随着越来越多的患者在早期得到诊断，对能够更快、更持久缓解症状的治疗方法的需求也日益增长，这推动了市场的成长。尤其是新型生物製药（例如Vyvgart等FcRn抑制剂）的开发，它们直接作用于免疫介导机制，从而提高了治疗效果并减少了副作用。

总体而言，注重提高治疗的复杂性和患者的治疗结果是推动慢性脱髓鞘多发性神经炎市场成长的关键因素。

然而，市场仍存在诸多挑战，阻碍市场扩张。首要障碍是治疗费用高。静脉注射免疫球蛋白（IVIG）、血浆置换和生物製药等治疗方法价格昂贵，而慢性脱髓鞘多发性神经炎神经病变需要长期持续治疗，频繁治疗给患者和医疗保健系统都带来了沉重的经济负担。此外，FcRn抑制剂等新型生物製药的高昂价格进一步加剧了这个问题，使得患者难以获得治疗，尤其是在医疗资源匮乏的地区。

另一个关键挑战是，慢性脱髓鞘多发性神经炎是一种罕见疾病，其症状与其他神经系统疾病如格林-巴利症候群（GBS）有重迭，经常导致误诊或延迟诊断，这常常导致在神经病变晚期才进行诊断，从而限制了治疗的效果。

此外，儘管新治疗方法的研发取得了进展，但某些亚型（例如难治性疾病）的治疗选择仍然有限。对于静脉注射免疫球蛋白（IVIG）和血浆置换等第一线治疗无效的患者，仍需要大量的有效第二线治疗。

最后，类固醇和静脉注射免疫球蛋白（IVIG）等传统疗法的副作用也会对一些患者造成困扰，使得长期治疗难以持续。因此，寻找副作用较少的有效治疗方法是该市场未来发展的关键挑战之一。

本报告调查了全球慢性脱髓鞘多发性神经炎市场，并总结了主要趋势、市场影响因素分析、法律制度、技术和专利分析、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家、竞争格局的详细分析以及主要企业的概况。

目录

执行摘要

第一章全球慢性脱髓鞘多发性神经炎市场：产业展望

• 市场趋势
• 法律规范
• 流行病学分析
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

2. 全球慢性脱髓鞘多发性神经炎市场（依通路）

• 医院药房
• 零售药局
• 网路药局

第三章全球慢性脱髓鞘多发性神经炎市场（依给药途径）

• 静脉
• 口服
• 其他的

4. 全球慢性脱髓鞘多发性神经炎市场（按地区）

• 北美洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 欧洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 世界其他地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

5. 全球慢性脱髓鞘多发性神经炎市场：竞争格局与公司概况

• 关键策略和发展
  • M&A
  • 协同活动
  • 业务扩展和资金筹措
  • 产品发布和核准
  • 其他活动
• 公司简介
  • Sanofi
  • Grifols, SA
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • AstraZeneca s (Alexion Pharmaceuticals, Inc.)
  • Argenx SE
  • Amgen (Horizon Therapeutics plc)
  • Biogen Inc.
  • GlaxoSmithKline (Human Genome Sciences, Inc.)
  • Pfizer Inc.
  • Takeda Pharmaceutical Company

第六章调查方法

Global Chronic Inflammatory Demyelinating Polyneuropathy Market, Analysis and Forecast: 2025-2035

Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder that primarily affects the peripheral nervous system. It is characterized by inflammation and demyelination (damage to the protective covering of nerves) of the nerve fibers, which leads to muscle weakness, sensory disturbances, and reduced reflexes. Chronic inflammatory demyelinating polyneuropathy is considered the chronic counterpart of Guillain-Barre syndrome (GBS), although chronic inflammatory demyelinating polyneuropathy tends to progress more slowly and is often recurrent.

Chronic inflammatory demyelinating polyneuropathy occurs when the body's immune system mistakenly attacks the myelin sheath, which insulates nerve fibers and allows for efficient nerve signal transmission. As a result, nerve conduction becomes impaired, leading to symptoms such as numbness, tingling, weakness, and pain in the limbs. Over time, if left untreated, Chronic inflammatory demyelinating polyneuropathy can cause permanent nerve damage and disability.

The disease can affect individuals of any age but is most commonly diagnosed in adults between the ages of 40 and 60. The cause of Chronic inflammatory demyelinating polyneuropathy is not fully understood, but it is thought to involve genetic predisposition and environmental factors that trigger an immune response. Chronic inflammatory demyelinating polyneuropathy is often treated with therapies that modify the immune system, such as intravenous immunoglobulin (IVIG), plasma exchange, and immunosuppressive drugs.

Early diagnosis and treatment are crucial for preventing long-term disability and improving the patient's quality of life. With proper management, many individuals with Chronic inflammatory demyelinating polyneuropathy can experience symptom relief and regain lost functionality.

One of the key drivers of the Chronic Inflammatory Demyelinating Polyneuropathy market is the growing demand for innovative and effective treatments. As awareness of Chronic inflammatory demyelinating polyneuropathy increases, both among healthcare providers and patients, there is a significant rise in the diagnosis rate of the disease. This, in turn, is driving the demand for more advanced therapies to manage the condition, especially as traditional treatments like IVIG (intravenous immunoglobulin) and plasma exchange may not be effective for all patients. The introduction of targeted biologic therapies and oral immunosuppressive treatments has opened up new treatment avenues, providing more personalized and effective care options for Chronic inflammatory demyelinating polyneuropathy patients.

Additionally, the increased awareness of Chronic inflammatory demyelinating polyneuropathy, improved diagnostic capabilities, and the growing prevalence of autoimmune diseases globally are contributing to the expanding patient pool. As more patients are diagnosed early, the need for innovative therapies that can offer faster, more sustained relief from symptoms is driving market growth. Furthermore, the development of new biologic therapies like FcRn inhibitors (e.g., Vyvgart) is addressing the immune-mediated mechanisms at the core of Chronic inflammatory demyelinating polyneuropathy, leading to better patient outcomes and fewer side effects.

Overall, the focus on advancing treatment options and improving patient outcomes is a key factor driving the growth of the Chronic inflammatory demyelinating polyneuropathy market.

Despite the growth of the Chronic Inflammatory Demyelinating Polyneuropathy market, several challenges continue to hinder its progress. One of the primary obstacles is the high cost of treatment, particularly for therapies such as intravenous immunoglobulin (IVIG), plasma exchange, and biologic therapies. These treatments can be expensive, especially considering that Chronic inflammatory demyelinating polyneuropathy often requires long-term management with frequent administration, leading to significant financial burden for both patients and healthcare systems. In addition, the high cost of novel biologic treatments, such as FcRn inhibitors, further compounds this challenge, limiting accessibility, particularly in regions with limited healthcare resources.

Another key challenge is the underdiagnosis and misdiagnosis of Chronic inflammatory demyelinating polyneuropathy. Given its rare nature and the overlap of symptoms with other neurological disorders like Guillain-Barre syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy is often misdiagnosed or diagnosed at later stages when nerve damage has already occurred. This delay in diagnosis can lead to worsened patient outcomes and a lack of timely intervention, affecting the effectiveness of treatment.

Additionally, while there has been significant progress in the development of new therapies, the lack of treatment options for specific subtypes of Chronic inflammatory demyelinating polyneuropathy, such as refractory Chronic inflammatory demyelinating polyneuropathy, remains a major hurdle. Some patients do not respond adequately to first-line therapies like IVIG or plasma exchange, and finding effective second-line treatments for these patients remains an area of unmet need.

Finally, side effects from traditional treatments like steroids and IVIG can be problematic for some patients, limiting their ability to adhere to long-term treatment regimens. As a result, finding therapies that are both effective and have fewer side effects remains a critical challenge in the Chronic inflammatory demyelinating polyneuropathy market.

In conclusion, while the chronic inflammatory demyelinating polyneuropathy market is experiencing growth, costly treatments, diagnostic challenges, limited treatment options for refractory cases, and side effects continue to present barriers that need to be addressed to fully realize the potential of Chronic inflammatory demyelinating polyneuropathy market.

The global Chronic Inflammatory Demyelinating Polyneuropathy market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Grifols, Kedrion Biopharma, Octapharma, Alexion Pharmaceuticals (now part of AstraZeneca), Argenx, Horizon Therapeutics (acquired by Amgen), and Biogen are at the forefront of providing treatments for chronic inflammatory demyelinating polyneuropathy. These companies are heavily involved in the development of intravenous immunoglobulin (IVIG) therapies, which are the mainstay of chronic inflammatory demyelinating polyneuropathy treatment. In addition, Argenx has introduced Vyvgart (efgartigimod), a FcRn inhibitor, which has shown promise in treating chronic inflammatory demyelinating polyneuropathy by modulating the immune system and reducing autoantibody activity.

As the market for chronic inflammatory demyelinating polyneuropathy treatments expands, these companies are also investing in new, innovative therapies that go beyond traditional immunoglobulin treatments. Biogen and Horizon Therapeutics, for example, are exploring biologic therapies and immune modulators, which can offer more targeted treatments for patients with chronic inflammatory demyelinating polyneuropathy. The competition is also driven by the increasing demand for personalized treatments and more effective solutions that can provide long-term relief, as current therapies often involve regular infusions and do not cure the disease.

These leading companies are contributing to the growing range of treatment options for chronic inflammatory demyelinating polyneuropathy, ultimately improving patient outcomes and quality of life. As the disease remains underdiagnosed in many cases, the focus on early diagnosis and innovative treatments is expected to drive further growth in the chronic inflammatory demyelinating polyneuropathy market.

Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation:

Segmentation 1: by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Segmentation 2: by Route of Administration

• Intravenous
• Oral
• Others

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The global Chronic Inflammatory Demyelinating Polyneuropathy market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in biomarker identification and genomic testing allowing for more targeted and effective treatments for patients with chronic inflammatory demyelinating polyneuropathy. This approach is enabling healthcare providers to tailor therapies to individual patients, improving outcomes and reducing side effects.

Additionally, innovative therapies are reshaping the treatment landscape. For example, FcRn inhibitors like Vyvgart (efgartigimod) from Argenx are offering a new way to treat chronic inflammatory demyelinating polyneuropathy by modulating the immune system to reduce the autoantibodies that attack peripheral nerves. This has opened up new possibilities for patients who do not respond well to traditional intravenous immunoglobulin (IVIG) treatments.

There is also a rise in the use of biologic therapies and immune modulators, which are moving beyond conventional IVIG treatments and targeting the underlying immune processes more specifically. Companies like Biogen and Horizon Therapeutics are developing therapies that offer more targeted, long-term relief for chronic inflammatory demyelinating polyneuropathy patients.

Chronic inflammatory demyelinating polyneuropathy market is also benefiting from improved diagnostic techniques that allow for earlier and more accurate identification of chronic inflammatory demyelinating polyneuropathy. With better awareness and more advanced tools, physicians are able to detect chronic inflammatory demyelinating polyneuropathy earlier, leading to timely interventions that can reduce disease progression and improve patient quality of life.

Finally, increased patient advocacy and awareness campaigns are helping to raise the profile of chronic inflammatory demyelinating polyneuropathy, ensuring that more patients are diagnosed and treated appropriately. These efforts are helping drive demand for new therapies and solutions, accelerating the growth of the chronic inflammatory demyelinating polyneuropathy market.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), ($Billion), 2023-2035

• 2.1 Hospital Pharmacy
• 2.2 Retail Pharmacy
• 2.3 Online Pharmacy

3. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), ($Billion), 2023-2035

• 3.1 Intravenous
• 3.2 Oral
• 3.3 Others

4. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (Region), ($Billion), 2023-2035

• 4.1 North America
  • 4.1.1 Key Findings
  • 4.1.2 Market Dynamics
  • 4.1.3 Market Sizing and Forecast
    • 4.1.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.1.3.1.1 U.S.
• 4.2 Europe
  • 4.2.1 Key Findings
  • 4.2.2 Market Dynamics
  • 4.2.3 Market Sizing and Forecast
    • 4.2.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.2.3.1.1 Germany
      • 4.2.3.1.2 U.K.
      • 4.2.3.1.3 France
      • 4.2.3.1.4 Italy
• 4.3 Asia Pacific
  • 4.3.1 Key Findings
  • 4.3.2 Market Dynamics
  • 4.3.3 Market Sizing and Forecast
    • 4.3.3.1 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.3.3.1.1 China
      • 4.3.3.1.2 Japan
• 4.4 Rest of the World
  • 4.4.1 Key Findings
  • 4.4.2 Market Dynamics
  • 4.4.3 Market Sizing and Forecast

5. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Competitive Landscape and Company Profiles

• 5.1 Key Strategies and Development
  • 5.1.1 Mergers and Acquisitions
  • 5.1.2 Synergistic Activities
  • 5.1.3 Business Expansions and Funding
  • 5.1.4 Product Launches and Approvals
  • 5.1.5 Other Activities
• 5.2 Company Profiles
  • 5.2.1 Sanofi
    • 5.2.1.1 Overview
    • 5.2.1.2 Top Products / Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Target Customers/End-Users
    • 5.2.1.5 Key Personnel
    • 5.2.1.6 Analyst View
  • 5.2.2 Grifols, S.A.
    • 5.2.2.1 Overview
    • 5.2.2.2 Top Products / Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers/End-Users
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 Kedrion Biopharma Inc.
    • 5.2.3.1 Overview
    • 5.2.3.2 Top Products / Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers/End-Users
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Octapharma AG
    • 5.2.4.1 Overview
    • 5.2.4.2 Top Products / Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers/End-Users
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View
  • 5.2.5 AstraZeneca s (Alexion Pharmaceuticals, Inc.)
    • 5.2.5.1 Overview
    • 5.2.5.2 Top Products / Product Portfolio
    • 5.2.5.3 Top Competitors
    • 5.2.5.4 Target Customers/End-Users
    • 5.2.5.5 Key Personnel
    • 5.2.5.6 Analyst View
  • 5.2.6 Argenx SE
    • 5.2.6.1 Overview
    • 5.2.6.2 Top Products / Product Portfolio
    • 5.2.6.3 Top Competitors
    • 5.2.6.4 Target Customers/End-Users
    • 5.2.6.5 Key Personnel
    • 5.2.6.6 Analyst View
  • 5.2.7 Amgen (Horizon Therapeutics plc)
    • 5.2.7.1 Overview
    • 5.2.7.2 Top Products / Product Portfolio
    • 5.2.7.3 Top Competitors
    • 5.2.7.4 Target Customers/End-Users
    • 5.2.7.5 Key Personnel
    • 5.2.7.6 Analyst View
  • 5.2.8 Biogen Inc.
    • 5.2.8.1 Overview
    • 5.2.8.2 Top Products / Product Portfolio
    • 5.2.8.3 Top Competitors
    • 5.2.8.4 Target Customers/End-Users
    • 5.2.8.5 Key Personnel
    • 5.2.8.6 Analyst View
  • 5.2.9 GlaxoSmithKline (Human Genome Sciences, Inc.)
    • 5.2.9.1 Overview
    • 5.2.9.2 Top Products / Product Portfolio
    • 5.2.9.3 Top Competitors
    • 5.2.9.4 Target Customers/End-Users
    • 5.2.9.5 Key Personnel
    • 5.2.9.6 Analyst View
  • 5.2.10 Pfizer Inc.
    • 5.2.10.1 Overview
    • 5.2.10.2 Top Products / Product Portfolio
    • 5.2.10.3 Top Competitors
    • 5.2.10.4 Target Customers/End-Users
    • 5.2.10.5 Key Personnel
    • 5.2.10.6 Analyst View
  • 5.2.11 Takeda Pharmaceutical Company
    • 5.2.11.1 Overview
    • 5.2.11.2 Top Products / Product Portfolio
    • 5.2.11.3 Top Competitors
    • 5.2.11.4 Target Customers/End-Users
    • 5.2.11.5 Key Personnel
    • 5.2.11.6 Analyst View

6. Research Methodology

List of Figures

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024 and 2035

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market Key Trends, Analysis

List of Tables

• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics, Impact Analysis
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024-2035